5月8日 - ** KBC证券将医疗科技公司飞利浦PHG.AS的评级从“增持”上调至“买入”，此前该公司公布了“稳健”的第一季度业绩并确认了业绩指引 (link)
** 尽管该券商预计第二季度表现将有所放缓，但飞利浦重申业绩展望令其“感到鼓舞”，而行业同行通用电气医疗 GEHC.O 和西门子医疗 SHLG.DE则下调了各自的预期
**报告称 ，飞利浦似乎更有能力抵消成本通胀和中国市场的逆风
** 尽管股价尚未充分反映该集团的强劲表现，但KBC认为其估值具有吸引力
** 根据LSEG数据，在覆盖飞利浦的23位分析师中，11位给予“强烈买入”或“买入”评级，12位给予“持有”评级，无人给予“卖出”评级
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.